Bonum Certa Men Certa

Insensitivity at the EPO's Management - Part II: Patent Office as a Cancer

Cancer letter



Summary: The EPO's stance on cancer recalled, in light of an altercation from 2013 (patent application no. EP03017743.0, appeal number T0598/12-3.3.02)

THE management of the EPO has resorted to what we consider both unethical and potentially illegal tactics. Union busting has taken such a high priority that every trick out of the book has been harnessed, with help from external (contracted) firms.

During Christmas we were contacted by a person who is able to show us just how jaw-dropping the EPO's management can be with regards (or disregard) to cancer. As a preparatory item, consider the following letter, which is nearly a couple of years old (emphasis with large fonts is ours):

Brussels, March 12th, 2014

M. Benoît Battistelli President - European Patent Office Erhardtstr. 27 80469 Munich Germany

Dear M. Battistelli,

My name is Francesco De Lorenzo and I am the President of the European Cancer Patient Coalition - ECPC, which represents 345 cancer patient organizations in 47 countries.

ECPC regularly engages with its members, EU institutions and international health and cancer care stakeholders to protect and enhance cancer patients’ rights in Europe, making sure that the voice of European citizens, affected by cancer, is heard.

That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent.

"That is why we are addressing you to express our concerns regarding the recent decision from the European Patent Office (EPO), Patent application no. EP03017743.0, appeal number T0598/12-3.3.02 on whether a clinical trial invalidates the request for a new drug patent."We believe that EPO’s position on the matter should take in due consideration the effects it will have on the future treatment of cancer patients and their ability to dispose of new and innovative drugs. We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine.

Clinical trials are research studies conducted on patients to evaluate the safety and efficacy of medicines intended to improve their health and provide the necessary scientific data and information to develop new medicines. ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure. Should this happen, there will eventually be serious implications for the development of life-saving medicines.

"We are concerned, in fact, that EPO’s current interpretation of the matter may make clinical trials more difficult to carry out and hence undermine critical innovation in medicine."Patients are not only a fundamental partner in the development of new drugs, but they are also those who will finally benefit from the innovation process. In particular, we strongly believe that it is natural that a patient may discuss his/her participation or clinical experience with their physician and family members. It is clear that patients participating in clinical trials should not be considered as members of the public, but rather key collaborators and important and voluntary participants of the trial. However, given their particular situation and knowledge level, patients cannot be compared either to other clinical trials actors, such as researchers. Hence patients cannot share the same confidentiality responsibility as researchers: this would, in fact, represent an unfair burden over the patients’ shoulders, which does not match patients’ level of biomedical and scientific understanding of clinical trials nor the reason for which they participate in them.

"ECPC believes that patent policy should encourage innovation, particularly innovation arising from clinical trials. A clinical trial cannot and should not be construed as a patent defeating disclosure."Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests. Reducing transparency will threaten the access to investigational drugs that clinical trials provide for patients. This access is of critical importance for cancer patients, particularly for those whose only treatment option may be a clinical trial.

Alternatively, delaying clinical trials until patent applications are filed, will add undue delay to the very time consuming process of developing a new medicine that could improve patients’ lives. Such patent policy also excludes any innovation that arises during a clinical trial.

"Aside from the pure legal perspective, it is to be expected that EPO decision on the 2013 case mentioned before, if implemented, will lead to reduced transparency and/or delay of implementation of new clinical trials, which are both to the detriment of patients’ interests."In conclusion, we strongly believe that the invention or findings related to a clinical trial should not be considered as “made available to the public” only because patients participate actively to the aforementioned trial. The patients’ unique status, in between collaborators and beneficiaries, makes them a key and vulnerable stakeholder, whose necessities are to be protected. Therefore, we would be glad to engage with EPO and all other relevant stakeholders in order to re-discuss the legal status and responsibilities of patients enrolled in clinical trials.

ECPC also believes that research should be encouraged and that public policy should remove barriers to the conduct of clinical trials, while keeping very high security standards and ensuring ethical conduct.

We hope that you will re-examine the decision in question for the benefit of patients. We remain at your disposal to further discuss the issue.

Sincerely,

Prof. F. De Lorenzo



To see how this relates to the series as a whole stay tuned for future parts. It is clear that patent scope has gone awry at the EPO, for the sake of protectionism, greed, and profit. Remember this when the EPO make claims on "productivity" (however misleading these claims can be) and ponder what this really translates into.

Recent Techrights' Posts

There's Nothing "Funny" About Attacking Free Speech and Software Freedom
persistent focus on the principal issues is very important
GNU/Linux Adoption in Africa, a Passageway Towards Freedom From Neo-Colonialism
Digi(tal)-Colonialism and/or Techolonialism are a thing. Can Africa flee the trap?
 
Links 06/12/2023: Many More December Layoffs
Links for the day
IRC Proceedings: Tuesday, December 05, 2023
IRC logs for Tuesday, December 05, 2023
PipeWire 1.0: Linux audio comes of age
Once upon a time, serious audio users like musicians and audio engineers had real trouble with Linux
This is How 'Linux' Foundation Presents Linux to the World
Right now it even picks Windows over Linux in some cases
Links 05/12/2023: Microsoft's Chatbot as Health Hazard
Links for the day
Professor Eben Moglen Explained How Software Patent Threats Had Changed Around 2014 (Alice Case) and What Would Happen Till 2025
clip aged reasonably well
CNN Contributes to Demolition of the Open Web
Reprinted with permission from Ryan Farmer
Eben Moglen on Encryption and Anonymity
The alternate net we need, and how we can build it ourselves
Yet More Microsofters Inside the Board of Mozilla (Which Has Just Outsourced Firefox Development to Microsoft's Proprietary Prison)
Do you want a browser controlled (and spied on) by such a company?
IRC Proceedings: Monday, December 04, 2023
IRC logs for Monday, December 04, 2023
GNU/Linux Now Exceeds 3.6% Market Share on Desktops/Laptops, According to statCounter
things have changed for Windows in China
Over at Tux Machines...
GNU/Linux news
Links 05/12/2023: Debt Brake in Germany and Layoffs at Condé Nast (Reddit, Wired, Ars Technica and More)
Links for the day
[Meme] Social Control Media Giants Shaping Debates on BSDs and GNU/Linux
listening to random people in Social Control Media
Reddit (Condé Nast), Which Has Another Round of Layoffs This Month, Incited People Against GNU/Linux Users (Divide and Rule, It's 2003 All Over Again!)
Does somebody (perhaps a third party) fan the flames?
Who Will Hold the Open Source Initiative (OSI) Accountable for Taking Bribes From Microsoft and Selling Out to Enable/Endorse Massive Copyright Infringement?
it does Microsoft advocacy
Using Gemini to Moan About Linux and Spread .NET
Toxic, acidic post in Gemini
Web Monopolist, Google, 'Pulls a Microsoft' by Hijacking/Overriding the Name of Competitor and Alternative to the Web
Gulag 'hijacking' 'Gemini'
Links 04/12/2023: Mass Layoffs at Spotify (Debt, Losses, Bubble) Once Again
Links for the day
ChatGPT Hype/Vapourware (and 'Bing') Has Failed, Google Maintains Dominance in Search
a growing mountain of debt and crises
[Meme] Every Real Paralegal Knows This
how copyright law works
Forging IRC Logs and Impersonating Professors: the Lengths to Which Anti-Free Software Militants Would Go
Impersonating people in IRC, too
IRC Proceedings: Sunday, December 03, 2023
IRC logs for Sunday, December 03, 2023
GNU/Linux Popularity Surging, So Why Did MakeUseOf Quit Covering It About 10 Days Ago?
It's particularly sad because some of the best articles about GNU/Linux came from that site, both technical articles and advocacy-centric pieces
Links 04/12/2023: COVID-19 Data Misused Again, Anti-Consumerism Activism
Links for the day